Plain-English translation of NCT05538208 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lupus Nephritis research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing , a medication that suppresses the immune system to reduce kidney inflammation in young people with lupus. The trial compares two different ways of calculating the dose: one based on body size (the standard method) and one based on blood levels of the medication (a personalized precision-dosing method). The goal is to find out which approach helps more patients achieve kidney disease remission.
Lupus kidney disease is serious and can lead to kidney failure, especially in children and young adults. Doctors want to know if personalizing the medication dose based on each patient's blood levels—rather than just using body size—can help more patients recover and reduce kidney damage.
You likely qualify if…
You likely don't qualify if…
You would take the medication twice daily for up to 53 weeks, divided into two parts. In the first 26 weeks, you would randomly receive either standard dosing or personalized dosing based on blood levels. Your doctor would check how well your kidneys are responding at week 26. If you had only a partial response in the first part, you might switch to the personalized dosing method in the second part. Throughout the study, you would attend regular visits for blood tests, kidney function checks, and questionnaires, and use a smartphone app to help track your medication.
AI-generated summary from trial data · Sep 15, 2026 · Not medical advice
United States